ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cost-Effectiveness"

  • Abstract Number: 1116 • ACR Convergence 2024

    Understanding the Prevalence, In-Hospital Mortality and Readmission Rates Amongst Pulmonary vs Cardiac Sarcoidosis Patients: Insights from a Nationwide Registry

    Shivang Chaudhary1, Kaushik Gokul1, Kishan Patel2, Simran Bhimani3, Yash Deshpande3, Adam Kilian1, Ravi Nayak1, Deana Mikhalkova1 and Chaitanya Rojulpote1, 1Saint Louis University, St. Louis, MO, 2Riverside Community Hospital, Riverside, CA, 3The Wright Center for graduate medical education, Scranton, PA

    Background/Purpose: Sarcoidosis is a complex, multisystemic disorder predominantly affecting the pulmonary system but can also involve extra-pulmonary organs such as the heart. Mortality in sarcoidosis…
  • Abstract Number: 1742 • ACR Convergence 2024

    Multi-Center Use of an Online Case-Based Simulation to Educate Pediatric Trainees on Musculoskeletal Complaints and High-Value Care

    Marina Latif1, Kyla Driest2, Erin Frank3, Allayne Stephans3, Stacey Tarvin4 and Angela Robinson5, 1Case Western Reserve University School of Medicine, Cleveland, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Rainbow Babies and Children's Hospital, Cleveland, OH, 4Indiana University School of Medicine, Indianapolis, IN, 5Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose:             Excessive healthcare spending in the United States remains a growing concern, and teaching high-value care is essential to combat wasted costs. It is…
  • Abstract Number: 2257 • ACR Convergence 2024

    Comparison of the Safety and Effectiveness of Originator Rituximab (Mabthera®) versus Biosimilar (Riximyo®) in Rheumatoid Arthritis: A Retrospective Unicentric Analysis

    Barbara Bayeh1, Fanny Neira1, Karina Bonfiglioli1, Nadia Aikawa2, ANA PAULA ASSAD1, Renata Miossi1, Fernando Souza3, Carlos Emilio Insfran Echauri1, Henrique Giardini1, Emily Figueiredo Neves Yuki1, Henrique Carriço Da Silva1, Andre Franco1, Diogo Domiciano1, Julio Moraes4, Eloisa Bonfa1, Carla Goncalves Schahin Saad3, Ana Cristina Medeiros-Ribeiro5 and Andrea Shimabuco3, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 2Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 3Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, 5Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil

    Background/Purpose: Immunobiological drugs emerged as a revolutionary option for treating inflammatory chronic rheumatic diseases, particularly rheumatoid arthritis (RA). However, the extremely high costs associated with…
  • Abstract Number: 0146 • ACR Convergence 2024

    Enhancing Pre-Biologic Response Modifier Screening for Coccidioidomycosis in Endemic Regions

    Bashar Tanous1, SRIKAR SAMA2, Nidaa Rasheed3 and Candice Reyes4, 1UCSF Fresno, Fresno, 2University of California San Francisco Fresno, Fresno, CA, 3UCSF Fresno, Fresno, CA, 4VACCHCS, Fresno, CA

    Background/Purpose: Biologic response modifiers (BRMs), also known as "biologics," have become essential tools in treating various chronic inflammatory conditions. However, the immunosuppression caused by these agents…
  • Abstract Number: 0212 • ACR Convergence 2024

    Costs of Hospitalization in Patients with SLE: An Analysis of the National Inpatient Sample

    Brandon Blau1, Kelsey Gripp1, Catherine MacLean2 and Bella Mehta2, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) is associated with significant health care utilization, medical costs, and increased risk of hospitalization. We aimed to characterize the reasons…
  • Abstract Number: 0274 • ACR Convergence 2024

    Cost-effectiveness of Low Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start-Low Go-Slow” Approach for Gout

    Yana Pryymachenko1, Ross Wilson1, Haxby Abbott1, Nicola Dalbeth2 and Lisa Stamp3, 1University of Otago, Dunedin, New Zealand, 2University of Auckland, Auckland, New Zealand, 3University of Otago, Christchurch, Christchurch, New Zealand

    Background/Purpose: To investigate the cost-effectiveness of low-dose colchicine prophylaxis for reducing gout flares when starting allopurinol using the “start-low go-slow” approach.Methods: This was a pre-planned…
  • Abstract Number: 0505 • ACR Convergence 2024

    UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi

    George Karpouzas1, Lixia Zhang2, Mark Zielinski2, Brian Cheng2 and Sherry Guardiano3, 1Harbor-UCLA Medical Center, Torrance, CA, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corporation, Keene, NH

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
  • Abstract Number: 0531 • ACR Convergence 2024

    Costs and Clinical Outcomes of the Rheumatoid Arthritis Medication Tapering Cohort

    Sama Hajizadeh1, Tyson Barrett2, Yue Yin3 and Dr Tarun Sharma4, 1Allegheny Health Network, Pittsburgh, 2Enterprise Data and Analytics, Highmark Health, Pittsburgh, 3Allegheny-Singer Research Institute, Allegheny Health Network, Pittsburgh, 4West Penn Hospital, Pittsburgh, PA

    Background/Purpose: Existing American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) guidelines regarding medication tapering in patients with rheumatoid arthritis (RA)…
  • Abstract Number: 0553 • ACR Convergence 2024

    Analyzing the Utilization of HLA-B27 Testing in a Large Rural Health System: Implications for Diagnostic Appropriateness

    Sanjeev Shrestha1, Angela Bobak2, Idorenyin Udoeyo3, Pradeep Puri4, Jordan Law5 and David Bulbin6, 1Geisinger Medical Center, Bloomsburg, PA, 2Geisinger Medical Center Internal Medicine Residency, Danville, PA, 3Geisinger Medical Center, Danville, PA, 4Geisinger Medical Center, Danville, 5Geisinger Health System, Danville, 6Geisinger Health System, Danville, PA

    Background/Purpose: Human leukocyte antigen (HLA)-B27 is linked to spondyloarthropathies (SpA), uveitis, and inflammatory bowel disease (IBD). By analyzing ordering diagnoses and final diagnoses during patient…
  • Abstract Number: 1046 • ACR Convergence 2024

    Shifting Paradigms in Drug Spending: A Study of Medicare Part D versus Emerging Pharmacy Models in Rheumatology

    Katherine Schoeffler, Stephanie Beveridge, Max Bouvette, Veera Durga Vaishnavi Kurra, Reema Moussa, Ryan Johnson, Camille Goerend, Nimrah Bader and Ryan Nipp, University of Oklahoma College of Medicine, Oklahoma City, OK

    Background/Purpose: Recent policy changes and competitive alternative drug pricing models present the potential for medication cost savings. In this study, we sought to assess the…
  • Abstract Number: 1050 • ACR Convergence 2024

    The Cost-effectiveness of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) for Patients with Knee Osteoarthritis and Obesity

    Daniel Betensky1, Jeffrey Katz1, Catherine Yang2, David Hunter3, Jamie Collins1, Candace Feldman1, Karen Smith1, Stephen Messier4, Jason Kim5, Faith Selzer6 and Elena Losina1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Brookline, MA, 3Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, 4Wake Forest University, Winston Salem, NC, 5Arthritis Foundation, Atlanta, GA, 6Brigham and Women's Hospital, Amesbury, MA

    Background/Purpose: Weight-loss has been shown to alleviate knee osteoarthritis (OA) symptoms in persons with OA and obesity. Utilization of GLP1RA medications has increased rapidly. These…
  • Abstract Number: 0169 • ACR Convergence 2023

    Added Value of Anti-HMGCR and Anti-SRP Antibodies in the Diagnosis of Immune Mediated Necrotizing Myopathy: An Outcome and Cost Comparison from the USA Perspective

    Alejandro Figueroa-Lara1, Mary Ann Aure2 and Carmen Andalucia1, 1Werfen, San Diego, CA, 2Werfen, Chula Vista, CA

    Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) is a subgroup of immune-mediated myopathies (IMM). The diagnosis of IMNM relied on the presence of proximal muscle weakness, high…
  • Abstract Number: 0299 • ACR Convergence 2023

    Trends and Outcomes of Hospitalized Patients with Idiopathic Inflammatory Myopathy and Venous Thromboembolism: A Nationwide Inpatient Sample Analysis from US (2016-2019)

    Haseeb Chaudhary1, Biraj Shrestha2, Sarah Abi Doumeth3 and Maya Mattar4, 1Case Western Reserve University, Westlake, OH, 2Tower Health System, Reading, PA, 3Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, 4Louis Stokes VA Medical Center, Cleveland, OH

    Background/Purpose: Recent evidence suggests increased prevalence of venous thromboembolism (VTE) in patients with idiopathic inflammatory myopathies (IIM). The literature on the clinical implications of VTE…
  • Abstract Number: 0335 • ACR Convergence 2023

    Meta-Analysis of the Cost-Effectiveness of Social Media Advertising as a Recruitment Tool

    Vladislav Tsaltskan1, Roel Baez2 and Gary Firestein1, 1University of California San Diego, San Diego, CA, 2UC San Diego Health, San Diego, CA

    Background/Purpose: Recruitment of study participants is challenging and can incur significant costs, particularly for studies of rheumatic disease or other rare conditions. Social media advertising…
  • Abstract Number: 0431 • ACR Convergence 2023

    Senescence and Cell Exhaustion in CD4+ and CD8+ Lymphocytes in Rheumatoid Arthritis Patients in Remission Without Treatment

    Rodolfo Jiménez-Soto1, Luis llorente2, Guadalupe Lima1, Luisa Alanis Saenz1, Amairani Gomez Rodriguez1, Hilda Marin Lopez1, Erik Cimé-Aké1 and Juan Jakez-Ocampo1, 1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: T cells are important among the several risk factors and immunological markers implicated in rheumatoid arthritis (RA). The goal of this study was to…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology